Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leiomyoma 4Papillomavirus Infections 3Inflammation 2Frailty 2Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Squamous Intraepithelial Lesions 1Radiodermatitis 1Prostatic Neoplasms 1Papilloma 1Liver Neoplasms 1Liver Cirrhosis 1Fibrosis 1Esophageal Neoplasms 1Deglutition Disorders 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Atypical Squamous Cells of the Cervix 1

Interventions

Fluorouracil 218Leucovorin 201Oxaliplatin 191Irinotecan 148Bevacizumab 107Capecitabine 93Cetuximab 89Folfox protocol 54Chemotherapy, Adjuvant 34Panitumumab 30pembrolizumab 23Nivolumab 22Colonoscopy 22Gemcitabine 20Magnetic Resonance Spectroscopy 19Floxuridine 19IFL protocol 18Celecoxib 18Radiotherapy 17Neoadjuvant Therapy 17Early Intervention, Educational 17Drug Therapy 17Laparoscopy 14Cyclophosphamide 14Counseling 14trifluridine tipiracil drug combination 13regorafenib 13XELOX 13Exercise 13Erlotinib Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Colonic Neoplasms × epigallocatechin gallate × Clear all
NCT02891538 2025-09-04

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Active not recruiting
51 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡